《自然》杂志近日发表了一项突破性研究，研究人员成功利用CRISPR-Cas12a2系统实现了RNA触发的细胞杀伤功能。这一发现为精准医学和靶向治疗开辟了全新路径。

CRISPR-Cas12a2是一种新型的CRISPR系统，与广泛使用的Cas9不同，它能够在识别特定RNA序列后激活细胞杀伤机制。这意味着科学家可以设计系统，仅在目标细胞表达特定RNA时触发杀伤作用，而不会影响其他健康细胞。

研究人员指出，这项技术在癌症治疗领域具有巨大潜力。例如，可以设计系统仅识别和杀死表达癌细胞特异性RNA标志物的细胞，从而实现高度精准的靶向治疗，大幅减少传统化疗的副作用。

此外，该技术在抗病毒治疗中也展现出应用前景。通过识别病毒RNA，系统可以选择性地清除被病毒感染的细胞，而不影响未感染的健康组织。

该研究由多个国际研究团队合作完成，论文已在《自然》杂志正式发表。学术界认为这是CRISPR技术从基因编辑工具向细胞级精准治疗迈进的重要里程碑。

Nature Publishes Breakthrough: CRISPR-Cas12a2 Achieves RNA-Triggered Cell Killing

Nature has published a groundbreaking study in which researchers successfully used the CRISPR-Cas12a2 system to achieve RNA-triggered cell killing. This discovery opens entirely new pathways for precision medicine and targeted therapy.

CRISPR-Cas12a2 is a novel CRISPR system that, unlike the widely used Cas9, can activate cell-killing mechanisms upon recognizing specific RNA sequences. This means scientists can design systems that trigger killing only when target cells express specific RNA, without affecting other healthy cells.

Researchers noted that this technology has enormous potential in cancer treatment. For example, systems could be designed to selectively identify and kill cells expressing cancer-specific RNA markers, enabling highly precise targeted therapy while dramatically reducing the side effects of traditional chemotherapy.

Additionally, the technology shows promise in antiviral treatment. By identifying viral RNA, the system can selectively clear virus-infected cells without affecting uninfected healthy tissue.

The study was completed by multiple international research teams and has been formally published in Nature. The academic community considers this a significant milestone in CRISPR’s evolution from a gene-editing tool to cell-level precision therapy.